Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6

MLA

Ariel Hammerman, et al. “Oral versus Subcutaneous Semaglutide for Prevention of Major Adverse Cardiovascular Events: Cost per Outcome Analysis of SUSTAIN-6 and PIONEER-6.” Postgraduate Medicine, vol. 134, no. 7, June 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9d4f7b46887c8f3efa21e66730e980a6&authtype=sso&custid=ns315887.

APA

Ariel Hammerman, Candace Makeda Moore, Enis Aboalhasan, Joseph Azuri, & Ronen Arbel. (2022). Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6. Postgraduate Medicine, 134(7).

Chicago

Ariel Hammerman, Candace Makeda Moore, Enis Aboalhasan, Joseph Azuri, and Ronen Arbel. 2022. “Oral versus Subcutaneous Semaglutide for Prevention of Major Adverse Cardiovascular Events: Cost per Outcome Analysis of SUSTAIN-6 and PIONEER-6.” Postgraduate Medicine 134 (7). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9d4f7b46887c8f3efa21e66730e980a6&authtype=sso&custid=ns315887.